Viyash Life Sciences PVT LTD
Ramakant Singani has a diverse and extensive work experience in the finance sector. Ramakant currently serves as the Chief Financial Officer at Viyash Life Sciences PVT LTD since September 2021. Prior to this role, they held the position of Vice President and Head GMO Finance at Dr. Reddy's Laboratories from March 2011 to August 2021.
Before joining Dr. Reddy's Laboratories, Ramakant worked as the General Manager - Finance & SCM at GVK Biosciences Pvt Ltd from February 2006 to March 2011. In the same company, they also served as the General Manager responsible for Accounts, Costing & MIS for the Medicinal Chemistry SBU, which contributed to 70% of the Revenues. Their responsibilities included accounts payable for all the SBUs and monthly performance reporting with tracking of key metrics.
Prior to GVK Biosciences Pvt Ltd, Ramakant worked at Dr. Reddy's Laboratories Limited as the Senior Manager - Finance from November 2000 to February 2006. In this role, they were responsible for sales and receivables accounting, monitoring and reporting of receivables from approximately 2000 customers, and payment of commission and reimbursements to C&Fs across India and product franchisees.
In their early career, Ramakant held the position of Deputy Manager at Tecumseh Products India Limited from August 1994 to November 2000. Ramakant was responsible for MIS and costing, including monthly performance estimation, reporting to the parent company as per US Gaap, and analysis of performance.
Overall, Ramakant Singani has gained extensive experience and expertise in finance, accounting, and management roles throughout their career.
Ramakant Singani obtained their B.Com(Hons) degree from The Indian Institute of Management & Commerce in the year 1991 to 1994. Later, they pursued their Associate membership at the Institute of Cost and Works Accountants of India from 1993 to 1996.
This person is not in any teams
This person is not in any offices
Viyash Life Sciences PVT LTD
We are an integrated pharmaceutical company with a strong portfolio of niche APIs and advanced Intermediates. Viyash and its subsidiaries operate 10 manufacturing facilities with a combined capacity over 2000 KL and diversified capabilities in every aspect - small/large volume, potent / non-potent, regulated / semi-regulated markets. We have a robust R&D infrastructure with a combined network of 3 R&D facilities and over 160 scientists with expertise across several technologies and complex reactions. Diversified mix of API portfolio across multiple therapy areas such as ARV, CV, CNS, Analgesics, Antibiotics, Antihistamines, Diabetes, GI, Anticoagulants, Oncology, etc. Our strong R&D and manufacturing capabilities are based on two cornerstones that define us – High Quality and Cost efficiency..